Acumen Pharmaceuticals (ABOS) Total Non-Current Liabilities (2023 - 2025)

Acumen Pharmaceuticals' Total Non-Current Liabilities history runs 3 years deep, the most recent figure standing at $52.4 million for Q4 2025.

• In Q4 2025, Total Non-Current Liabilities fell 8.11% year-over-year to $52.4 million; the TTM figure through Dec 2025 stood at $52.4 million (down 8.11% YoY), while the FY2025 annual figure was $52.4 million, down 8.11% from the prior year.
• Total Non-Current Liabilities came in at $52.4 million for Q4 2025 at Acumen Pharmaceuticals, up from $49.0 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $57.0 million in Q4 2024 to a low of $42.9 million in Q4 2023.
• A 3-year average of $50.8 million and a median of $50.7 million in 2025 frame the typical range for Total Non-Current Liabilities.
• Across the five-year window, Total Non-Current Liabilities jumped 33.03% in 2024 and dropped 8.11% in 2025, its largest moves.
• Acumen Pharmaceuticals' Total Non-Current Liabilities stood at $42.9 million in 2023, then soared by 33.03% to $57.0 million in 2024, then fell by 8.11% to $52.4 million in 2025.
• According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $52.4 million, $49.0 million, and $54.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.

Peer Comparison